|

anti-CD19 CAR T cell therapy Clinical Trials

3 actively recruiting trials

Pipeline

Phase 1/2: 3

Top Sponsors

  • Peking University Third Hospital1
  • Miltenyi Biomedicine GmbH1
  • Kara Yakhteh Tajhiz Azma Company1

Indications

  • Lupus2
  • Polymyositis1
  • ANCA Associated Vasculitis (AAV)1
  • Antiphospholipid Syndrome1
  • Systemic Sclerosis1

Other3 trials

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Phase 1/2
Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/2
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.